Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cognetivity Neurosciences Ltd C.CGN

Alternate Symbol(s):  CGNSF

Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial and consumer environments for potentially allowing early diagnosis of dementia. The Company’s ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from providing a measure of cognitive function, to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The Company serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.


CSE:CGN - Post by User

Post by AwareInvestoron Sep 01, 2021 8:23am
77 Views
Post# 33793242

Cognetivity’s Assessment Tool To Be Deployed At KetamineOne

Cognetivity’s Assessment Tool To Be Deployed At KetamineOne
Cognetivity Neurosciences will soon see its cognitive assessment tool for the early detection of changes in cognitive performance arrive in North America. The company this morning announced an agreement with KetamineOne Capital for the deployment of the tool at its clinics across the continent.
<< Previous
Bullboard Posts
Next >>